BR9915127A - Cystine derivatives as therapeutic agents for diseases related to matrix metalloprotease - Google Patents

Cystine derivatives as therapeutic agents for diseases related to matrix metalloprotease

Info

Publication number
BR9915127A
BR9915127A BR9915127-8A BR9915127A BR9915127A BR 9915127 A BR9915127 A BR 9915127A BR 9915127 A BR9915127 A BR 9915127A BR 9915127 A BR9915127 A BR 9915127A
Authority
BR
Brazil
Prior art keywords
aromatic
diseases
heterocyclic
carbocyclic
same
Prior art date
Application number
BR9915127-8A
Other languages
Portuguese (pt)
Inventor
Frank Grams
Hans-Willi Krell
Herbert Leinert
Gerd Zimmermann
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BR9915127A publication Critical patent/BR9915127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE CISTINA COMO AGENTES TERAPêUTICOS PARA DOENçAS RELACIONADAS A METALOPROTEASE DE MATRIZ"<D>. O assunto da presente invenção são as composições farmacêuticas contendo derivados de cistina não peptídica de fórmula geral (I) em que R~ 1~ e R~ 3~ podem ser iguais ou diferentes e são selecionados dentre hidrogênio, um anel heterocíclico ou carbocíclico, aromático ou não-aromático, ou um grupo alquila saturado ou não-saturado, linear ou ramificado de 1 a 15 átomos de carbono que pode ser interrompido por um heteroátomo e que pode ser substituído por um anel heterocíclico ou carbocíclico, aromático ou não-aromático. R~ 2~ e R~ 4~ podem ser iguais ou diferentes e são selecionados dentre hidrogênio, um grupo alquila saturado ou não-saturado, linear ou ramificado de 1 a 15 átomos de carbono que pode ser interrompido por um heteroátomo e que pode ser substituído por um anel heterocíclico ou carbocíclico, aromático ou não-aromático, e A é uma ligação de valência ou um grupo -CO-, -SO~ 2~-, -NHCO- ou -NHCS -O-CO-, seus sais farmacologicamente aceitáveis e formas opticamente ativas dos mesmos e veículos farmaceuticamente aceitáveis, para o tratamento de doenças selecionadas dentre crescimento de tumor e metástase, doenças inflamatórias como artrite osteo- e reumatóide, osteoporose, esclerose múltipla, periodontite, restenose, doenças causadas por bactérias como meningite, envelhecimento da pele induzido por sol e doença de Alzheimer e novos compostos.Invention Patent: <B> "CYSTINE DERIVATIVES AS THERAPEUTIC AGENTS FOR DISEASES RELATED TO MATRIX METALOPROTEASE" <D>. The subject of the present invention is pharmaceutical compositions containing non-peptide cystine derivatives of general formula (I) in which R ~ 1 ~ and R ~ 3 ~ can be the same or different and are selected from hydrogen, an aromatic heterocyclic or carbocyclic ring or non-aromatic, or a saturated or unsaturated, linear or branched alkyl group of 1 to 15 carbon atoms that can be interrupted by a heteroatom and that can be replaced by a heterocyclic or carbocyclic, aromatic or non-aromatic ring. R ~ 2 ~ and R ~ 4 ~ can be the same or different and are selected from hydrogen, a saturated or unsaturated, linear or branched alkyl group of 1 to 15 carbon atoms that can be interrupted by a heteroatom and that can be substituted by a heterocyclic or carbocyclic, aromatic or non-aromatic ring, and A is a valence bond or a -CO-, -SO ~ 2 ~ -, -NHCO- or -NHCS -O-CO- group, their pharmacologically salts acceptable and optically active forms of the same and pharmaceutically acceptable vehicles, for the treatment of diseases selected from tumor growth and metastasis, inflammatory diseases such as osteo- and rheumatoid arthritis, osteoporosis, multiple sclerosis, periodontitis, restenosis, diseases caused by bacteria such as meningitis, sun-induced skin aging and Alzheimer's disease and new compounds.

BR9915127-8A 1998-11-06 1999-11-05 Cystine derivatives as therapeutic agents for diseases related to matrix metalloprotease BR9915127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98121073 1998-11-06
PCT/EP1999/008460 WO2000027378A2 (en) 1998-11-06 1999-11-05 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases

Publications (1)

Publication Number Publication Date
BR9915127A true BR9915127A (en) 2001-07-31

Family

ID=8232930

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915127-8A BR9915127A (en) 1998-11-06 1999-11-05 Cystine derivatives as therapeutic agents for diseases related to matrix metalloprotease

Country Status (11)

Country Link
EP (1) EP1143960A2 (en)
JP (1) JP2002529404A (en)
KR (1) KR20010100983A (en)
CN (1) CN1346272A (en)
AR (1) AR025135A1 (en)
AU (1) AU1379600A (en)
BR (1) BR9915127A (en)
CA (1) CA2348946A1 (en)
TR (1) TR200101222T2 (en)
WO (1) WO2000027378A2 (en)
ZA (1) ZA200103605B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101332157B (en) * 1998-10-09 2012-01-11 味之素株式会社 Cysteine derivatives
JP2002226457A (en) * 2001-02-02 2002-08-14 Ajinomoto Co Inc New cystine derivative and inflammation factor activation inhibitor
EP1871420A4 (en) 2005-04-15 2010-09-22 Univ North Carolina Methods of facilitating cell survival using neurotrophin mimetics
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010319349B2 (en) 2009-11-12 2015-07-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
USRE49579E1 (en) * 2015-06-08 2023-07-18 University Public Corporation Osaka Non-peptidic GAPDH aggregation inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478002A (en) * 1975-02-12 1977-06-29 Ecnpk Biolog I Mediko Biolog P Pharmaceutical composition having anti-tumour activity

Also Published As

Publication number Publication date
TR200101222T2 (en) 2001-12-21
JP2002529404A (en) 2002-09-10
CN1346272A (en) 2002-04-24
CA2348946A1 (en) 2000-05-18
AR025135A1 (en) 2002-11-13
WO2000027378A3 (en) 2001-09-20
EP1143960A2 (en) 2001-10-17
ZA200103605B (en) 2001-12-11
KR20010100983A (en) 2001-11-14
AU1379600A (en) 2000-05-29
WO2000027378A2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
GT200100137A (en) PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES.
UY24409A1 (en) METALOPROTEASE MATRIX INHIBITORS
TR199900255T2 (en) Muscarinic antagonists
BR0314611A (en) Thiazole compounds for the treatment of neurodegenerative disorders
PA8472301A1 (en) ISOTIAZOLE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS
UY26143A1 (en) USEFUL HETEROCYCLIC DERIVATIVES AS ANTI-CANCER AGENTS
SV2002000232A (en) NEW BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS REF. PC 10608ABCZ / BB
BR0108610A (en) Azapolycyclic compounds condensed with aryl
BR0109161A (en) Beta-carbolines replaced with ikb-kinase inhibiting activity
BR9713186A (en) 1,3-diheterocyclic metalloprotease inhibitors
PT939627E (en) PENTAFLUOROBENZENOSULFONAMIDAS AND ANALOGOS
DE68914292D1 (en) Composition for the treatment of ischemic disorders in organs.
AR018139A1 (en) A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
BR9811093A (en) Pyridines replaced with 2-amino-6- (2-substituted 4-phenoxy)
PA8485101A1 (en) NEW MACROLID ANTIBIOTICS.
PT911331E (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
UY29823A1 (en) SUBSTITUTED DERIVATIVES OF 7-CHLORINE-3H-IMIDAZOL- (4,5-B) PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THE PREPARATION OF THE SAME AND APPLICATIONS
SE9601677D0 (en) New use
ATE206926T1 (en) USE OF A PHOSPHORIC ACID DIESTER FOR PRODUCING A MEDICINAL PRODUCT FOR THE TREATMENT OF ACNE
BR9915127A (en) Cystine derivatives as therapeutic agents for diseases related to matrix metalloprotease
BR0317027A (en) Arylene carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents
BR9815920A (en) Azaheterocyclic compounds used to treat neurological disorders and hair loss
GT200100169A (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2.
ATE307145T1 (en) USE OF PHENYLHYDRAZONE DERIVATIVES AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS
PA8471801A1 (en) HYGROMYCIN A DERIVATIVES

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired